Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Title
Intervention Indication Therapeutic Area Year Actions
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893) Atopic dermatitis Dermatology 2018 View  |  Download
Durvalumab in combination with Tremelimumab and Standard of Care Chemotherapy for EGFR Negative, ALK Negative Metastatic NSCLC– First Line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Durvalumab in combination with Tremelimumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Head and neck cancer Head and Neck Cancer 2018 View  |  Download
Edaravone for amyotrophic lateral sclerosis Edaravone (IV) (Radicava; MCI-186; Radicut; Edaravone) Motor neurone disease (MND or ALS) Neurology 2018 View  |  Download
Eflornithine in combination with Sulindac for Familial Adenomatus Polyposis Eflornithine (CPP-1X; Difluoromethylornithine; DFMO; Vaniqa; eflornithine hydrochloride monohydrate) , Sulindac Familial adenomatous polyposis (FAP) Gastroenterology , Genetic Disorders 2018 View  |  Download
Elotuzumab in combination with pomalidomide and low-dose dexamethasone for relapsed and refractory multiple myeloma – third line Dexamethasone (dexamethasone sodium metasulfobenzoate) , Elotuzumab (Empliciti; BMS-901608; HuLuc63) , Pomalidomide (Imnovid; CC-4047; Pomalyst) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Emapalumab for Primary Haemophagocytic Lymphohistiocytosis Emapalumab (NI-0501; Gamifant) Primary haemophagocytic lymphohistiocytosis (HLH) Genetic Disorders , Immunology 2018 View  |  Download
Enasidenib for Relapsed or Refractory Acute Myeloid Leukaemia (AML) with an Isocitrate Dehydrogenase 2 (IDH2) Mutation Enasidenib (Idhifa; AG-221; CC-90007) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2018 View  |  Download
Entrectinib for ROS1 fusion positive, locally advanced or metastatic non-small cell lung cancer Entrectinib (RXDX-101) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Entrectinib for the Treatment of NTRK-fusion Positive Solid Tumours in Adult and Paediatric Patients Entrectinib (RXDX-101) Solid tumours Haematological Cancer and Lymphomas , Oncology 2018 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications